文献速递肾小球疾病

刺激免疫检查点分子BTLA减轻实验性新月体性肾小球肾炎

Stimulation of Immune Checkpoint Molecule B and T-Lymphocyte Attenuator Alleviates Experimental Crescentic Glomerulonephritis.
PubMed 文献 · J Am Soc Nephrol · 2023-06-26

研究在新月体性肾小球肾炎小鼠模型中探究BTLA的作用,发现BTLA缺陷小鼠肾炎加重,而激动性抗BTLA抗体可减轻病变,提示抗体调节BTLA可能成为人类肾小球疾病的治疗策略。

要点

  • BTLA缺陷小鼠新月体性肾炎加重,与肾脏Th1细胞浸润增加有关。
  • BTLA缺陷的效应T细胞可逃避Treg抑制,而Treg抑制功能保留。
  • 激动性抗BTLA抗体在体内减轻肾炎,抑制致病性T效应细胞并促进Treg扩增。

核心结论

  • 在新月体性肾小球肾炎模型中,BTLA信号有效抑制致病性Th1细胞并促进调节性T细胞。
  • 通过BTLA刺激抑制T细胞介导的炎症可能对多种涉及急性肾小球肾炎的疾病具有相关性。

研究设计与样本

  • 研究在BTLA缺陷小鼠和野生型同窝对照中诱导肾毒性肾炎(NTN),即新月体性肾小球肾炎小鼠模型,并在疾病诱导后不同时间点评估疾病严重程度。
  • 通过流式细胞术、RNA测序以及树突状细胞和T细胞功能的体外实验全面评估免疫学变化。
  • 将细胞转移至Rag1KO小鼠以确认体外发现,并在体内评估激动性抗BTLA抗体治疗NTN的潜力。

主要发现

  • BTLA缺陷小鼠发生加重的NTN,由浸润肾脏的Th1细胞增加驱动。
  • 单细胞RNA测序显示肾脏T细胞活化增加和免疫反应的正向调节。
  • BTLA缺陷的调节性T细胞(Treg)在体外和体内表现出保留的抑制功能,但BTLA缺陷的T效应细胞逃避了Treg抑制。
  • 给予激动性抗BTLA抗体通过抑制致病性T效应细胞和促进Treg扩增,显著减轻NTN。

临床怎么用

  • 作者认为,基于抗体的BTLA调节可能代表人类肾小球疾病的一种治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Treatment of acute, crescentic glomerulonephritis (GN) consists of unspecific and potentially toxic immunosuppression. T cells are central in the pathogenesis of GN, and various checkpoint molecules control their activation. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown potential for restraining inflammation in other T-cell-mediated disease models. To investigate its role in GN in a murine model of crescentic nephritis, the authors induced nephrotoxic nephritis in BTLA-deficient mice and wild-type mice. They found that BTLA has a renoprotective role through suppression of local Th1-driven inflammation and expansion of T regulatory cells and that administration of an agonistic anti-BTLA antibody attenuated experimental GN. These findings suggest that antibody-based modulation of BTLA may represent a treatment strategy in human glomerular disease. BACKGROUND: Modulating T-lymphocytes represents a promising targeted therapeutic option for glomerulonephritis (GN) because these cells mediate damage in various experimental and human GN types. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown its potential to restrain inflammation in other T-cell-mediated disease models. Its role in GN, however, has not been investigated. METHODS: We induced nephrotoxic nephritis (NTN), a mouse model of crescentic GN, in Btla -deficient ( BtlaKO ) mice and wild-type littermate controls and assessed disease severity using functional and histologic parameters at different time points after disease induction. Immunologic changes were comprehensively evaluated by flow cytometry, RNA sequencing, and in vitro assays for dendritic cell and T-cell function. Transfer experiments into Rag1KO mice confirmed the observed in vitro findings. In addition, we evaluated the potential of an agonistic anti-BTLA antibody to treat NTN in vivo . RESULTS: The BtlaKO mice developed aggravated NTN, driven by an increase of infiltrating renal Th1 cells. Single-cell RNA sequencing showed increased renal T-cell activation and positive regulation of the immune response. Although BTLA-deficient regulatory T cells (Tregs) exhibited preserved suppressive function in vitro and in vivo , BtlaKO T effector cells evaded Treg suppression. Administration of an agonistic anti-BTLA antibody robustly attenuated NTN by suppressing nephritogenic T effector cells and promoting Treg expansion. CONCLUSIONS: In a model of crescentic GN, BTLA signaling effectively restrained nephritogenic Th1 cells and promoted regulatory T cells. Suppression of T-cell-mediated inflammation by BTLA stimulation may prove relevant for a broad range of conditions involving acute GN.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Diefenhardt P, Braumann M, Schömig T, et al. Stimulation of Immune Checkpoint Molecule B and T-Lymphocyte Attenuator Alleviates Experimental Crescentic Glomerulonephritis. J Am Soc Nephrol. 2023. PMID: 37367205. doi:10.1681/ASN.0000000000000159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。